-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, F8e/QREJMIYJXXHjA8jzdl5dvlr6tfBXXrMnFtIvmRPyMHUbms3ecXzp4ynn73XW vzI1+c1L9UG9FkRahmBCTQ== 0001016504-04-000061.txt : 20040914 0001016504-04-000061.hdr.sgml : 20040914 20040914154148 ACCESSION NUMBER: 0001016504-04-000061 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20040914 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20040914 DATE AS OF CHANGE: 20040914 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTEGRATED BIOPHARMA INC CENTRAL INDEX KEY: 0001016504 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133035216 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31668 FILM NUMBER: 041029662 BUSINESS ADDRESS: STREET 1: 201 ROUTE 22 CITY: HILLSIDE STATE: NJ ZIP: 07205 BUSINESS PHONE: 9739260816 MAIL ADDRESS: STREET 1: 201 ROUTE 22 CITY: HILLSIDE STATE: NJ ZIP: 07205 FORMER COMPANY: FORMER CONFORMED NAME: INTEGRATED HEALTH TECHNOLOGIES INC DATE OF NAME CHANGE: 20020912 FORMER COMPANY: FORMER CONFORMED NAME: CHEM INTERNATIONAL INC DATE OF NAME CHANGE: 19960716 8-K 1 inb8ksep14_2004.txt INTEGRATED BIOPHARMA, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 14, 2004 Integrated BioPharma, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-28876 22-2407475 (Commission File Number) (IRS Employer Identification No.) 225 Long Avenue Hillside, New Jersey 07205 (Address of Principal Executive Offices) (Zip Code) (973) 926-0816 (Registrant's Telephone Number, Including Area Code) (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 7.01. Regulation FD Disclosure On September 14, 2004, Integrated BioPharma, Inc., a Delaware corporation (the "Company"), issued a press release stating that NuCycle Therapy, Inc., INB's wholly owned subsidiary, has formed a Scientific Advisory Board (SAB). The press release is attached as an exhibit to this Report. Item 9.01. Financial Statements and Exhibits (c) Exhibits. Exhibit No. Description 99.1 Press Release issued by Integrated BioPharma, Inc. on September 14, 2004. 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized. INTEGRATED BIOPHARMA, INC. Date: September 14, 2004 By: /s/ Eric Friedman Eric Friedman Vice President and Chief Financial Officer EX-99 2 exhibit99_1.txt INTEGRATED BIOPHARMA Exhibit 99.1 NEWS RELEASE for September 14, 2004 Contact: Brian Kennedy Eric Friedman, CFO Allen & Caron Inc Integrated BioPharma Inc 212 691 8087 888 319 6962 brian@allencaron.com e.friedman@chemintl.com NUCYCLE THERAPY, INC. FORMS A SCIENTIFIC ADVISORY BOARD HILLSIDE, NJ (September 14, 2004) Integrated BioPharma Inc (Amex: INB) is pleased to announce that NuCycle Therapy, Inc., INB's wholly owned subsidiary, has formed a Scientific Advisory Board (SAB), that consists of medical doctors and professionals with multidisciplinary talents. The purpose of the SAB is to provide NuCycle with guidance on the development and application of its plant-produced human therapeutic proteins and vaccines. Integrated BioPharma Chairman and CEO, E. Gerald Kay said, "This prestigious group of individuals will provide NuCycle with the guidance needed to create a new production platform for human therapeutics and vaccines. Because of its patented technology, NuCycle is in a unique position to change the manner in which vaccines are produced." The Scientific Advisory Board consists of the following members, indicated in alphabetical order: Orn Adalsteinsson, Ph.D., President of NuCycle Therapy, Inc. Dr. Adalsteinsson has held several executive positions in the life science industry during his 25-year career. As former President of DCV Biologics LP, a joint venture between DuPont and Conagra, he developed nationally distributed nutraceutical products. Dr. Adalsteinsson has held numerous managerial positions during his tenure at DuPont and Procter & Gamble. Burt Ensley, Ph.D. is the former President and Vice President of Research of NuCycle Therapy, Inc. Dr. Ensley has directed research, field demonstrations and evaluation of biological and related physical/chemical technologies applicable to the treatment of hazardous wastes. He was a research manager at Amgen, Inc. where he developed methods and applications for the genetic engineering of metabolic operons. Dr. Ensley holds numerous patents. Reinhard Gluck, PhD., Chief Scientific Officer and Member of the Executive Board of Directors of Berna Biotech Ltd (formerly Swiss Serum & Vaccine Institute). Dr. Gluck is world renowned for his expertise in vaccine development and production, and he has been responsible for major vaccine products that are sold worldwide. Adalsteinn Gudmundsson, MD, Medical Chief of Hrafnista, the largest chain of nursing homes in Iceland. Dr. Gudmundsson is actively involved in several human research projects, including an ongoing 30 million dollar geriatric study. Dr. Gudmundsson holds a clinical assistant professor position at the University of Wisconsin, Madison. William F. Hartman, Ph.D., Vice President of Fraunhofer USA. Dr. Hartman, former Johns Hopkins University professor of mechanics and materials science, has over twenty-five years of executive experience in the development and management of technological businesses. He has served as a director of five technology companies, including two start-up companies. He is responsible for the strategic growth and management of the non-profit organization, Fraunhofer USA, that runs five technology centers throughout the United States. Michel Klein, MD, Chief Executive Officer, CANVAC, Canadian Network for Vaccines and Immunotherapeutics. He has held the position of professor of immunology at the University of Toronto, and he is the former Vice President of Science and Technology, Aventis Pasteur Group. Dr. Klein has led a large team of scientists developing major vaccine products, some of which are being marketed worldwide. Martin Lipkin, MD, Professor of Medicine, Weill Medical College of Cornell University, Director of Clinical Research Strang Cancer Prevention Center - Strang Cancer Research Laboratory at Rockefeller University, New York City. Dr. Lipkin is head of a group of investigators who have developed one of the largest collections of mouse models used in pre-clinical studies for cancer prevention and cancer treatment trials. Zivko L. Nikolov, Ph.D., Dow Chemical Professor at Texas A&M University. He is the former Vice President of Bioprocess Development and Production at Prodigene Inc. Dr. Nikolov is a known authority in bioprocessing of transgenic plants, purification development and scale-up of plant-produced therapeutic proteins and vaccines. Michael Pariza, Ph.D., Director of the Food Research Institute (FRI), Wisconsin Distinguished Professor, and Chair of the Department of Food Microbiology and Toxicology, University of Wisconsin, Madison. Dr. Pariza holds numerous patents, including several in the area of conjugated linoleic acids (CLA), which have resulted in major nutraceutical products in Europe and in the United States. Dr. Pariza is a world authority on food safety and has testified on food safety issues in front of the United States Congress. Dean Stull, Ph.D., President of Paxis Pharmaceuticals, Inc. Dr. Stull has served in executive positions and founded several companies in the areas of pharmaceutical and chemical technologies. He has served on several for-profit and non-profit boards including the Colorado Institute for Research in Biotechnology and the Governors Committee on High Technology. Dr. Stull has facilitated commercialization of technologies related to the pharmaceutical, food and dietary supplement industries. Vidadi Yusibov, Ph.D., Chief Scientific Director of Fraunhofer USA, Center for Molecular Biotechnology. Dr. Yusibov holds numerous patents and leads a sizeable group of scientists in carrying out some of the pioneering programs of plant-produced human therapeutic proteins and vaccines. Karl Zimmerman, MD, Practicing Internist in Unionville, Pennsylvania. Dr. Zimmerman runs a large private practice in the southern part of Pennsylvania and is a leading innovator in the application/development of nutraceuticals for use along with conventional pharmaceutical therapies. About Integrated BioPharma Inc (INB) INB serves the pharmaceutical, biotech and nutraceutical industries. Through several wholly owned subsidiaries, INB develops, manufactures and distributes more than 130 products worldwide. Its subsidiary, Paxis Pharmaceuticals, Inc., develops and operates a state-of-the-art GMP facility for the production and sale of paclitaxel and related drugs. Through its biotech subsidiary, NuCycle Therapy, Inc., INB is developing human therapeutics and preventive cancer compounds in transgenic plants. Further information is available at www.iBioPharma.com. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission. -----END PRIVACY-ENHANCED MESSAGE-----